Search Share Prices
AZN Shares - AstraZeneca takes back autoimmune drug, sells rights to blood pressure treatments
AstraZeneca PLC (LON:AZN) is take back the rights to brazikumab, an antibody currently being tested to treat inflammatory bowel diseases such as Crohn’s disease. The drug was licensed to Allergan plc ...
AstraZeneca (LON:AZN) PT Raised to GBX 8,810 at Liberum Capital
AstraZeneca (LON:AZN) had its target price raised by Liberum Capital from GBX 8,300 ($109.18) to GBX 8,810 ($115.89) in a report released on Wednesday morning, Borsen Zeitung reports. They currently ...
AstraZeneca (LON:AZN) PT Set at GBX 6,000 by Goldman Sachs Group
AstraZeneca (LON:AZN) has been assigned a GBX 6,000 ($78.93) price objective by analysts at Goldman Sachs Group in a research report issued on Thursday, Borsen Zeitung reports. The brokerage currently ...
AstraZeneca earnings to be hit by US$100mln write-down after trial stops
An independent data monitoring committee recommended to stop phase III of the trial on Epanova, which is still marketed in the US for other treatments AstraZeneca PLC’s (LON:AZN) fourth-quarter ...